← Back to Analyst Consensus 
DFTX Buy
Definium Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 24
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Sep 15, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 15, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Sep 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 14, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Sep 11, 2026 | RBC Capital | reiterate | Outperform → Outperform | — | 55% |
| Aug 18, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
| Aug 14, 2026 | Maxim Group | maintain | Buy → Buy | — | 42% |
| Aug 13, 2026 | Jones Trading | maintain | Buy → Buy | — | 50% |
| Aug 13, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 13, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 13, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Aug 12, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Aug 7, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Jul 27, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Jul 24, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Jul 8, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Jun 30, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 24, 2026 | Jones Trading | maintain | Buy → Buy | — | 50% |
| Jun 23, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Jun 23, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 22, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Jun 16, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 8, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Apr 17, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Apr 16, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 10, 2026 | Piper Sandler | initiate | — → Overweight | — | 54% |
| Mar 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Outperform | $25 | 53% |
| Jan 30, 2026 | Jefferies | initiate | — → Buy | $30 | 52% |
| Jan 23, 2026 | RBC Capital | maintain | Outperform → Outperform | $36 | 55% |
Price Target Trend
Jul 30, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days